GSK's cancer drug combination meets primary goal in late-stage trial

[cafead]

via GSK (GSK.L) said on Monday that a combination of its cancer drugs Zejula and Jemperli, when as used as a maintenance therapy following Jemperli plus chemotherapy, met the main goal of a late-stage trial to treat a certain type of endometrial cancer.

article source